FROM PAPER TO PLATFORMS: THE DIGITAL REINVENTION OF REGULATORY AFFAIRS

Regulatory Affairs (RA) has emerged as a cornerstone of the pharmaceutical and healthcare ecosystem, bridging innovation, compliance, and patient safety. As drug development becomes increasingly complex and globalized, RA ensures that pharmaceuticals, biologics, medical devices, and novel therapies meet rigorous national and international regulatory standards throughout their lifecycle—from discovery and preclinical evaluation to clinical trials, approval, and post-marketing surveillance. Modern RA integrates digital submission platforms, artificial intelligence, real-world evidence, and patient-centric approaches to streamline regulatory processes, enhance transparency, and accelerate access to safe and effective therapies. Harmonized frameworks, including CTD, eCTD, ACTD, and ICH guidelines, facilitate cross-border approvals and reduce redundancy. The discipline now extends to advanced therapies such as gene and cell therapies, biosimilar, and digital health innovations, reflecting its evolving scope and strategic significance. This review synthesizes the critical roles, regulatory frameworks, emerging trends, and future directions of RA, highlighting its indispensable contribution to public health, innovation, and sustainable growth in the global healthcare landscape.